– The increasing demand for non-invasive testing methodologies and rising chronic disease incidence are driving the demand for the market.
– Market Size – USD 3.80 billion in 2019, Market Growth – CAGR of 26.2%, Market Trends – Rise in the use of Cell-Free DNA (cfDNA) Testing to treat chromosomal disorders.
VANCOUVER, BC, Oct. 20, 2020 /PRNewswire/ — The Global Cell-Free DNA (cfDNA) Testing Market is forecast to be worth USD 22.41 Billion by 2027, according to a new report by Emergen Research. The Global Cell-Free DNA (cfDNA) Testing Market is projected to grow significantly during the forecast period due to increased incidences of cancers, rising prevalence of chromosome abnormalities in babies due to an increasing number of late pregnancy, and growing demand for non-invasive testing procedures. Moreover, increasing investments by governments to implement advanced therapeutic technology in hospitals is also expected to boost the market during the forecast period.
However, expensive equipment and a lack of skilled healthcare professionals would restrain the market growth in the forecast timeframe.
Request free sample of this research report at: https://www.emergenresearch.com/request-sample/156
Key Highlights From The Report
In August 2019, Agilent Technologies Inc. announced the acquisition of a leading manufacturer of innovative healthcare equipment, BioTek Instruments, Inc. This acquisition will expand Agilent’s product portfolio and its presence in North America.
Cell-free fetal DNA is a non-invasive procedure and, therefore, does not pose a health risk of CVS (chorionic villus sampling) or amniocentesis, like pain and any slight chance of infection. Due to these benefits, the cell-free fetal DNA segment held the largest market share of 48.8% in the Global Cell-Free DNA (cfDNA) Testing Market in 2019.
The MPSS technology segment is estimated to dominate the global market with a CAGR of 26.7%, owing to the advantage of producing a measurable profile of gene expression in cells or tissues.
The gynecology segment is anticipated to lead the market during the forecast period, as the cell-free DNA approach is being used to detect genetic issues of baby and to diagnose pregnancy complications such as pregnancy loss.
North America accounted for the largest market share of around 33.6% in 2019, owing to the increasing chronic diseases and pregnancy problems in this region due to the changing lifestyles. Besides, the adoption of advanced technology in hospitals is also expected to boost the market shortly.
Key participants include Sequenom, Inc., Quest Diagnostics, Illumina Inc., Agilent Technologies, Inc., Guardant Health, Inc., Biodesix, Inc., Allenex AB, Roche Holdings AG, Biocept, Inc., and CareDx, Inc., among others.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/cell-free-dna-market
Emergen Research has segmented the Global Cell-Free DNA (cfDNA) Testing Market on the basis of type, technology, application, and region:
Type Outlook (Revenue, USD Billion; 2017-2027)
Technology Outlook (Revenue, USD Billion; 2017-2027)
Application Outlook (Revenue, USD Billion; 2017-2027)
Order Now: https://www.emergenresearch.com/select-license/156
Find more similar research insights by Emergen Research:
Wound Cleanser Products Market By Product Type (Wetting Agents, Antiseptics, Moisturizers, Others), By Form Type (Sprays, Solutions, Wipes, Foams, Others), By End